

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>OPTISCAN IMAGING LIMITED</b>
<b>ABN</b>	<b>81 077 771 987</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Camile Farah
<b>Date of last notice</b>	18 July 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none"><li>1. Phoenix Financial Pty Ltd &lt;Phoenix Super Fund A/C&gt; (the Director is a beneficiary of the fund)</li><li>2. Dr Marie Anne Teresa J Matias (Director's spouse)</li><li>3. Camile Farah and Marie Matias&lt;Farah &amp; Matias Family A/C&gt;</li></ol>
<b>Date of change</b>	9 March 2025
<b>No. of securities held prior to change</b>	<p><b>Direct</b></p> <p>3,000,000 Unlisted options exercisable at \$0.1925 on or before 9 March 2025</p> <p>9,000,000 Unlisted options exercisable at \$0.1925 on or before 9 March 2027</p> <p><b>Indirect</b></p> <ol style="list-style-type: none"><li>1. 666,667 Fully paid ordinary shares</li><li>2. 24,985 Fully paid ordinary shares</li><li>3. 8,000,000 Fully paid ordinary shares</li></ol>

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Class</b>	Direct: Unlisted Options exercisable at \$0.1925 on or before 9 March 2025
<b>Number acquired</b>	Nil
<b>Number disposed</b>	Direct: 3,000,000 Options
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	-
<b>No. of securities held after change</b>	<p><b>Direct</b> 9,000,000 Unlisted options exercisable at \$0.1925 on or before 9 March 2027</p> <p><b>Indirect</b></p> <ol style="list-style-type: none"> <li>1. 666,667 Fully paid ordinary shares</li> <li>2. 24,985 Fully paid ordinary shares</li> <li>3. 8,000,000 Fully paid ordinary shares</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Unlisted options expired un-exercised

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.